No respite yet on German retrospective re-pricing of Novartis’ gliptins (or other drugs)
This article was originally published in Scrip
A Berlin court has decided that Novartis must submit its dossier for an AMNOG reimbursement review of Galvus (vildagliptin) by 31 March, even thought the same court is still deciding whether Novartis should have to face the reimbursement review at all. The Swiss company had challenged the review on the basis that the process for retrospective comparisons was not clear.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.